Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2015, Article ID 135298, 6 pages
http://dx.doi.org/10.1155/2015/135298
Research Article

Evaluation of Podoplanin in Oral Leukoplakia and Oral Squamous Cell Carcinoma

Department of Oral Pathology and Microbiology, SMBT Dental College and Hospital, Sangamner, Maharashtra 422608, India

Received 26 June 2015; Revised 19 September 2015; Accepted 20 September 2015

Academic Editor: Kazuhisa Bessho

Copyright © 2015 Ashok Patil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J.-Q. Feng, J.-G. Mi, L. Wu et al., “Expression of podoplanin and ABCG2 in oral erythroplakia correlate with oral cancer development,” Oral Oncology, vol. 48, no. 9, pp. 848–852, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Kawaguchi, A. K. El-Naggar, V. Papadimitrakopoulou et al., “Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 354–360, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Warnakulasuriya, N. W. Johnson, and I. van der Waal, “Nomenclature and classification of potentially malignant disorders of the oral mucosa,” Journal of Oral Pathology and Medicine, vol. 36, no. 10, pp. 575–580, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. J. Lee, W. K. Hong, W. N. Hittelman et al., “Predicting cancer development in oral leukoplakia: ten years of translational research,” Clinical Cancer Research, vol. 6, no. 5, pp. 1702–1710, 2000. View at Google Scholar · View at Scopus
  5. S. W. Lee and Y. W. Park, “Expression of endoglin and podoplanin in early and advanced oral squamous cell carcinoma,” Journal of the Korean Association of Oral and Maxillofacial Surgeons, vol. 38, no. 3, pp. 145–151, 2012. View at Publisher · View at Google Scholar
  6. V. Schacht, S. S. Dadras, L. A. Johnson, D. G. Jackson, Y.-K. Hong, and M. Detmar, “Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors,” The American Journal of Pathology, vol. 166, no. 3, pp. 913–921, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Wicki, F. Lehembre, N. Wick, B. Hantusch, D. Kerjaschki, and G. Christofori, “Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton,” Cancer Cell, vol. 9, no. 4, pp. 261–272, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Raica, A. M. Cimpean, and D. Ribatti, “The role of podoplanin in tumor progression and metastasis,” Anticancer Research, vol. 28, no. 5, pp. 2997–3006, 2008. View at Google Scholar · View at Scopus
  9. M. A. A. Al-Rawi, R. E. Mansel, and W. G. Jiang, “Molecular and cellular mechanisms of lymphangiogenesis,” European Journal of Surgical Oncology, vol. 31, no. 2, pp. 117–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Shi, W. Liu, Z.-T. Zhou, Q.-B. He, and W.-W. Jiang, “Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 3, pp. 844–849, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. C. De Vicente, J. P. Rodrigo, T. Rodriguez-Santamarta, P. Lequerica-Fernández, E. Allonca, and J. M. García-Pedrero, “Podoplanin expression in oral leukoplakia: tumorigenic role,” Oral Oncology, vol. 49, no. 6, pp. 598–603, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Silverman Jr., M. Gorsky, and F. Lozada, “Oral leukoplakia and malignant transformation. A follow-up study of 257 patients,” Cancer, vol. 53, no. 3, pp. 563–568, 1984. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Ohno, H. Nakanishi, A. Abe et al., “Regional difference in intratumoral lymphangiogenesis of oral squamous cell carcinomas evaluated by immunohistochemistry using D2-40 and podoplanin antibody: an analysis in comparison with angiogenesis,” Journal of Oral Pathology and Medicine, vol. 36, no. 5, pp. 281–289, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Mashhadiabbas, F. Mahjour, S. B. Mahjour, F. Fereidooni, and F. S. Hosseini, “The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma,” Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, vol. 114, no. 2, pp. 240–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Ohta, A. Abe, F. Ohno et al., “Positive and negative regulation of podoplanin expression by TGF-β and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines,” Oral Oncology, vol. 49, no. 1, pp. 20–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. G. F. Huber, F. R. Fritzsche, L. Züllig et al., “Podoplanin expression correlates with sentinel lymph node metastasis in early squamous cell carcinomas of the oral cavity and oropharynx,” International Journal of Cancer, vol. 129, no. 6, pp. 1404–1409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. P. Rodrigo, D. García-Carracedo, M. V. González, G. Mancebo, M. F. Fresno, and J. García-Pedrero, “Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas,” Molecular Cancer, vol. 9, article 48, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Atsumi, G. Ishii, M. Kojima, M. Sanada, S. Fujii, and A. Ochiai, “Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431,” Biochemical and Biophysical Research Communications, vol. 373, no. 1, pp. 36–41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Miyazaki, E. Okamoto, P. González-Alva et al., “The significance of podoplanin expression in human inflamed gingiva,” Journal of Oral Science, vol. 51, no. 2, pp. 283–287, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. A. G. Zygogianni, G. Kyrgias, P. Karakitsos et al., “Oral squamous cell cancer: early detection and the role of alcohol and smoking,” Head and Neck Oncology, vol. 3, article 2, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Martín-Villar, B. Fernández-Munoz, M. Parsons et al., “Podoplanin associates with CD44 to promote directional cell migration,” Molecular Biology of the Cell, vol. 21, no. 24, pp. 4387–4399, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Toll, J. Gimeno-Beltrán, C. Ferrandiz-Pulido et al., “D2-40 immunohistochemical overexpression in cutaneous squamous cell carcinomas: a marker of metastatic risk,” Journal of the American Academy of Dermatology, vol. 67, no. 6, pp. 1310–1318, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Inoue, Y. Miyazaki, K. Kikuchi et al., “Podoplanin promotes cell migration via the EGF-Src-Cas pathway in oral squamous cell carcinoma cell lines,” Journal of oral science, vol. 54, no. 3, pp. 241–250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Wicki and G. Christofori, “The potential role of podoplanin in tumour invasion,” British Journal of Cancer, vol. 96, no. 1, pp. 1–5, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Cîmpean, M. Raica, D. A. Izvernariu, and D. Tǎtucu, “Lymphatic vessels identified with podoplanin: comparison of immunostaining with three different detection systems,” Romanian Journal of Morphology and Embryology, vol. 48, no. 2, pp. 139–143, 2007. View at Google Scholar · View at Scopus
  26. Y. Kato and M. K. Kaneko, “A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin,” Scientific Reports, vol. 4, article 5924, 2014. View at Publisher · View at Google Scholar · View at Scopus